Nello Mainolfi, Chief Executive Officer at Kymera Therapeutics, Inc. (KYMR), sold 30,000 shares at $111.44 ($3.4M) on 2026-10-01, disclosed to the SEC on 2026-10-01.
Scheduled sale ($3.4M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $111.44 | 3,525 | $393K | 11.5% |
| 2 | $112.42 | 5,506 | $619K | 18.1% |
| 3 | $113.24 | 4,876 | $552K | 16.2% |
| 4 | $114.43 | 7,601 | $870K | 25.5% |
| 5 | $115.40 | 8,230 | $950K | 27.8% |
| 6 | $116.12 | 262 |
| $30K |
| 0.9% |
| Total | $113.80 avg | 30,000 | $3.4M | 100% |
| Filing → |
| KYMR | SELL | 2026-04-29 | $2.4M | — | Filing → |
| KYMR | SELL | 2026-02-25 | $2.7M | — | Filing → |
| KYMR | SELL | 2025-12-31 | $4.7M | — | Filing → |